Glufosfamide threshold brain delivery
WebJan 31, 2005 · Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may play a role in the pathophysiology of schizophrenia. Elevated … WebBrain and Central Nervous System Tumors (1) Carcinoma, Small Cell Lung (1) Lung Cancer (1) ... Threshold Pharmaceuticals (3) Sign Up. Intervention New. glufosfamide (9) fluorouracil (1) gemcitabine (1) Study Results. Has …
Glufosfamide threshold brain delivery
Did you know?
WebMar 1, 2007 · 1. To evaluate the efficacy of glufosfamide in subjects with advanced soft tissue sarcoma as measured by objective response rate. Secondary Objectives: To … WebThere was an 18% increase in overall survival for glufosfamide that was not statistically significant: hazard ratio (HR) 0.85 (95% confidence interval (CI) 0.66-1.08, p=0.19). …
WebIn this way, glufosfamide targets cancer cells while reducing toxicity to normal cells. Glufosfamide has been evaluated in more than 450 patients in multiple clinical studies … WebJan 18, 2008 · Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that …
WebApr 6, 2000 · Arm II: Patients receive glufosfamide as in arm I. Patients are hydrated with excess physiological saline solution 4 hours before and for 3 hours after treatment with glufosfamide. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. ... Conditions: Brain and Central Nervous System Tumors . … WebJan 18, 2008 · Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform …
WebSep 28, 2006 · Last month the Company announced that it had completed enrollment in a pivotal phase 3 clinical trial evaluating glufosfamide for the potential second-line treatment of pancreatic cancer and a phase 2 clinical trial evaluating glufosfamide in combination with gemcitabine for the potential first-line treatment of pancreatic cancer.
WebMay 20, 2008 · 10591 Background: Glufosfamide is glucose linked to isophosphoramide mustard, the active metabolite of ifosfamide. Ifosfamide is known to have activity in soft tissue sarcoma. The objectives of this study are to evaluate the safety and efficacy of GLU in patients (pts) with soft tissue sarcoma. Methods: This 1-stage phase 2 study planned to … a saadi stkfupmWebGlufosfamide is a novel small molecule that has been evaluated by Threshold in a Phase 3 clinical trial and multiple Phase 2 clinical trials. Under the agreement, Eleison is … asa adidasWebGlufosfamide was compared to best supportive care on 303 randomised patients. There was an 18% increase in OS for glufosfamide that was not statistically significant: HR = 0.85, [0.66–1.08]; P = 0.19) [75]. A randomised phase II study evaluated raltitrexed with … A.L. Inselman, D.K. Hansen, in Encyclopedia of Toxicology (Third … Corinna Weber-Schöndorfer, Christof Schaefer, in Drugs During Pregnancy … In Meyler's Side Effects of Drugs (Sixteenth Edition), 2016. Organs and systems … The glycoconjugate drug (glufosfamide) exhibited 4.5-fold decreased toxicity in … asaad jandali md indianaWebDec 1, 2003 · Discussion. Glufosfamide showed a low hematological and non-hematological toxicity profile in GBM patients. The relatively large volume that was administrated in a short time (1000 ml in 60 min) did not cause increased edema or neurological deterioration during or shortly after the infusion, events that have been … asa adipositasWebDec 28, 2006 · Glufosfamide was generally well tolerated in combination with gemcitabine with no new unexpected adverse events. "We are pleased with these encouraging top-line results and look forward next year to additional six- and twelve-month survival data from this clinical trial," said Barry Selick, Ph.D., Threshold's chief executive officer. bangkok palace hotel tripadvisorWebOct 3, 2006 · October 3, 2006. Threshold Pharmaceuticals announced that under the FDA has granted orphan drug designation to the company's product candidate, glufosfamide, for the treatment of pancreatic cancer. Orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 … asa adsmWebFeb 2, 2005 · The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine. Detailed Description: This study, TH-CR … bangkok patio bar \u0026 restaurant